PE20020335A1 - Acetamida de benceno de alfa-acil- y alfa-heteroatomo-sustituido como activadores de la glucoquinasa - Google Patents
Acetamida de benceno de alfa-acil- y alfa-heteroatomo-sustituido como activadores de la glucoquinasaInfo
- Publication number
- PE20020335A1 PE20020335A1 PE2001000731A PE2001000731A PE20020335A1 PE 20020335 A1 PE20020335 A1 PE 20020335A1 PE 2001000731 A PE2001000731 A PE 2001000731A PE 2001000731 A PE2001000731 A PE 2001000731A PE 20020335 A1 PE20020335 A1 PE 20020335A1
- Authority
- PE
- Peru
- Prior art keywords
- alpha
- acil
- heteroatome
- dichloro
- acetyl
- Prior art date
Links
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical class NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 title 1
- 102000030595 Glucokinase Human genes 0.000 title 1
- 108010021582 Glucokinase Proteins 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 abstract 1
- GBRFVNIVLOASHK-UHFFFAOYSA-N 2-cyclohex-2-en-1-yloxy-2-(3,4-dichlorophenyl)-n-(methylcarbamoyl)acetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCCC=C1 GBRFVNIVLOASHK-UHFFFAOYSA-N 0.000 abstract 1
- PZDFZWWTLUQGLV-UHFFFAOYSA-N 2-cyclohexyloxy-2-(3,4-dichlorophenyl)-n-(methylcarbamoyl)acetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCCCC1 PZDFZWWTLUQGLV-UHFFFAOYSA-N 0.000 abstract 1
- -1 3,4-DICHLORO-PHENYL Chemical class 0.000 abstract 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical class [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical class O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229940124828 glucokinase activator Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/48—Y being a hydrogen or a carbon atom
- C07C275/50—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/18—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
SE REFIERE A UNA AMIDA DE FORMULA I DONDE R1 Y R2 SON H, HALO, CIANO, NITRO, ALQUILO, TIO, PERFLUOROALQUILOTIO, ALQUILOSULFONILO, PERFLUOROALQUILOSULFONILO, ENTRE OTROS; R3 ES ALQUILO C2-C4, CICLOALQUILO, CICLOALQUENILO, HETEROCICLOALQUILO; R4 ES CONHR5, R6; R6 ES UN ANILLO HETEROAROMATICO DE 5-6 MIEMBROS; R1 ES ALQUILOHIDROXILO, HALOALQUILO, (CH2)NCOOR7, CO-(CH2)n-(O)-OR8; n ES 0-4; R7, R8, R9, R10, R11, R12, R13 SON H, ALQUILO; X ES O, S, SULFONILO, CARBONILO. SON COMPUESTOS PREFERIDOS 1-[CICLOPENTILOXI-(3,4-DICLORO-FENIL)-ACETIL]-3-METIL-UREA; 1-[CICLOHEXILOXI-(3,4-DICLORO-FENIL)-ACETIL]-3-METIL-UREA, 1-[(CICLOHEX-2-ENILOXI)-(3,4-DICLORO-FENIL)-ACETIL]-3-METIL-UREA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO PARA LA PPREPARACION. EL COMPUESTO I ES ACTIVADOR DE GLUCOQUINASA Y PUEDE SER UTIL PARA EL TRATAMIENTO DE DIABETES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21987200P | 2000-07-20 | 2000-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020335A1 true PE20020335A1 (es) | 2002-04-30 |
Family
ID=22821104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000731A PE20020335A1 (es) | 2000-07-20 | 2001-07-19 | Acetamida de benceno de alfa-acil- y alfa-heteroatomo-sustituido como activadores de la glucoquinasa |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US6486184B2 (es) |
| EP (1) | EP1305301B1 (es) |
| JP (1) | JP4138478B2 (es) |
| KR (1) | KR100556323B1 (es) |
| CN (1) | CN1184214C (es) |
| AR (1) | AR032626A1 (es) |
| AT (1) | ATE297907T1 (es) |
| AU (2) | AU8760001A (es) |
| BR (1) | BR0112658A (es) |
| CA (1) | CA2416229C (es) |
| DE (1) | DE60111534T2 (es) |
| DK (1) | DK1305301T3 (es) |
| ES (1) | ES2243547T3 (es) |
| GT (1) | GT200100146A (es) |
| MX (1) | MXPA03000365A (es) |
| PA (1) | PA8522701A1 (es) |
| PE (1) | PE20020335A1 (es) |
| PT (1) | PT1305301E (es) |
| UY (1) | UY26850A1 (es) |
| WO (1) | WO2002008209A1 (es) |
| ZA (1) | ZA200300173B (es) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| EP1336607A1 (en) * | 2002-02-19 | 2003-08-20 | Novo Nordisk A/S | Amide derivatives as glucokinase activators |
| IL162620A0 (en) * | 2001-12-21 | 2005-11-20 | Novo Nordisk As | Amide derivatives as gk activators |
| MXPA04010605A (es) | 2002-04-26 | 2004-12-13 | Hoffmann La Roche | Fenilacetamidas substituidas y su uso como activadores de flucoquinasa. |
| MXPA05000130A (es) | 2002-06-27 | 2005-02-17 | Novo Nordisk As | Derivados de aril-carbonilo como agentes terapeuticos. |
| RU2340605C2 (ru) | 2002-06-27 | 2008-12-10 | Ново Нордиск А/С | Арилкарбонильные производные в качестве терапевтических средств |
| HK1079788A1 (zh) * | 2002-10-03 | 2006-04-13 | Novartis Ag | 适用於治疗2型糖尿病的作为葡萄糖激酶活化剂的取代的(噻唑-2-基)-酰胺或磺胺 |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| US7132425B2 (en) | 2002-12-12 | 2006-11-07 | Hoffmann-La Roche Inc. | 5-substituted-six-membered heteroaromatic glucokinase activators |
| AU2003294376A1 (en) * | 2003-01-06 | 2004-08-10 | Eli Lilly And Company | Heteroaryl compounds |
| PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| RU2381233C2 (ru) | 2003-09-30 | 2010-02-10 | Ново Нордиск А/С | Агонисты рецептора меланокортина |
| EP2298337B1 (en) | 2003-12-09 | 2017-02-22 | Novo Nordisk A/S | Regulation of food preference using GLP-1 agonists |
| CN102516240A (zh) | 2004-01-06 | 2012-06-27 | 诺和诺德公司 | 杂芳基脲及其作为葡糖激酶活化剂的用途 |
| ATE524479T1 (de) | 2004-04-02 | 2011-09-15 | Novartis Ag | Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren |
| JP2007530631A (ja) | 2004-04-02 | 2007-11-01 | ノバルティス アクチエンゲゼルシャフト | チアゾロピリジン誘導体、それを含む医薬組成物およびグルコキナーゼ介在性状態の処置法 |
| BRPI0510163A (pt) * | 2004-04-21 | 2007-10-02 | Prosidion Ltd | compostos de amidas tri(ciclo)-substituìdas |
| WO2005120492A1 (en) | 2004-06-11 | 2005-12-22 | Novo Nordisk A/S | Counteracting drug-induced obesity using glp-1 agonists |
| GB0418046D0 (en) * | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Eantioselective process |
| CA2576407A1 (en) * | 2004-08-12 | 2006-02-16 | Prosidion Limited | Substituted phenylacetamides and their use as glucokinase activators |
| WO2007006760A1 (en) * | 2005-07-08 | 2007-01-18 | Novo Nordisk A/S | Dicycloalkyl urea glucokinase activators |
| WO2007006761A1 (en) | 2005-07-08 | 2007-01-18 | Novo Nordisk A/S | Dicycloalkylcarbamoyl ureas as glucokinase activators |
| AU2006268406C1 (en) | 2005-07-09 | 2011-02-24 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| KR101446973B1 (ko) * | 2005-07-14 | 2014-10-07 | 트랜스테크 파르마 엘엘씨 | 우레아 글루코키나제 활성제 |
| ES2426345T3 (es) | 2005-07-20 | 2013-10-22 | Eli Lilly And Company | Compuesto unidos en posición 1-amino |
| KR20080040046A (ko) | 2005-08-31 | 2008-05-07 | 아스텔라스세이야쿠 가부시키가이샤 | 티아졸 유도체 |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| CN101272784A (zh) | 2005-09-29 | 2008-09-24 | 塞诺菲-安万特股份有限公司 | 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途 |
| GT200600428A (es) | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| AU2006310474A1 (en) * | 2005-11-03 | 2007-05-10 | Prosidion Ltd | Tricyclo substituted amides |
| SI1951658T1 (sl) | 2005-11-17 | 2012-11-30 | Lilly Co Eli | Antagonisti glukagonskega receptorja priprava interapevtska uporaba |
| US20070197532A1 (en) * | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
| WO2007104034A2 (en) | 2006-03-08 | 2007-09-13 | Takeda San Diego, Inc. | Glucokinase activators |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| JP5386350B2 (ja) | 2006-05-31 | 2014-01-15 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体 |
| US7888504B2 (en) | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| EP2086951B1 (en) | 2006-11-15 | 2011-12-21 | High Point Pharmaceuticals, LLC | Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes |
| US7902248B2 (en) | 2006-12-14 | 2011-03-08 | Hoffmann-La Roche Inc. | Oxime glucokinase activators |
| EP2091947A2 (en) | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Glucokinase activators |
| TW200831081A (en) * | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| JP2010515701A (ja) | 2007-01-09 | 2010-05-13 | ノボ・ノルデイスク・エー／エス | ウレアグルコキナーゼアクチベーター |
| JP5226008B2 (ja) | 2007-01-11 | 2013-07-03 | ノボ・ノルデイスク・エー／エス | ウレアグルコキナーゼアクチベーター |
| WO2008104994A2 (en) | 2007-02-28 | 2008-09-04 | Advinus Therapeutics Private Limited | 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application |
| KR20090121376A (ko) * | 2007-03-07 | 2009-11-25 | 교린 세이야꾸 가부시키 가이샤 | 글루코키나아제 활성화 물질 |
| WO2008116107A2 (en) * | 2007-03-21 | 2008-09-25 | Takeda San Diego, Inc. | Piperazine derivatives as glucokinase activators |
| ES2446932T3 (es) * | 2007-10-08 | 2014-03-10 | Advinus Therapeutics Private Limited | Derivados de acetamida como activadores de glucoquinasa, su procedimiento y aplicaciones en medicina |
| US9340506B2 (en) | 2007-10-08 | 2016-05-17 | Advinus Therapeutics Limited | Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| TW200934772A (en) * | 2008-01-15 | 2009-08-16 | Lilly Co Eli | Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide |
| JP5287730B2 (ja) | 2008-01-18 | 2013-09-11 | アステラス製薬株式会社 | フェニルアセトアミド誘導体 |
| HRP20150842T1 (hr) | 2008-04-28 | 2015-09-11 | Kyorin Pharmaceutical Co., Ltd. | Derivati ciklopentilakrilamida |
| PE20141375A1 (es) | 2008-05-16 | 2014-10-23 | Takeda San Diego Inc | Activadores de glucoquinasa |
| US8450494B2 (en) | 2009-06-22 | 2013-05-28 | Cadila Healthcare Limited | Disubstituted benzamide derivatives as glucokinase (GK) activators |
| WO2011013141A2 (en) | 2009-07-31 | 2011-02-03 | Cadila Healthcare Limited | Substituted benzamide derivatives as glucokinase (gk) activators |
| WO2011080755A1 (en) | 2009-12-29 | 2011-07-07 | Advinus Therapeutics Private Limited | Fused nitrogen heterocyclic compounds, process of preparation and uses thereof |
| WO2011095997A1 (en) | 2010-02-08 | 2011-08-11 | Advinus Therapeutics Private Limited | Benzamide compounds as glucokinase activators and their pharmaceutical application |
| BR112012021231A2 (pt) | 2010-02-26 | 2015-09-08 | Basf Plant Science Co Gmbh | método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto |
| WO2011104378A1 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Peptides for treatment of obesity |
| KR20130018410A (ko) | 2010-03-26 | 2013-02-21 | 노보 노르디스크 에이/에스 | 새로운 글루카곤 유사체 |
| EP2553086B1 (en) | 2010-03-31 | 2017-04-19 | The Scripps Research Institute | Reprogramming cells |
| EP2402327B1 (en) | 2010-06-29 | 2018-03-07 | Impetis Biosciences Ltd. | Acetamide compounds as glucokinase activators, their process and medicinal applications |
| EP2691108A1 (en) | 2011-03-28 | 2014-02-05 | Novo Nordisk A/S | Novel glucagon analogues |
| WO2013041678A1 (en) | 2011-09-23 | 2013-03-28 | Novo Nordisk A/S | Novel glucagon analogues |
| AU2014255608B2 (en) | 2013-04-18 | 2018-01-25 | Novo Nordisk A/S | Stable, protracted GLP-1/glucagon receptor co-agonists for medical use |
| EP3151852A1 (en) | 2014-06-04 | 2017-04-12 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
| CN111032680A (zh) | 2017-03-15 | 2020-04-17 | 诺和诺德股份有限公司 | 能够与黑皮质素4受体结合的双环化合物 |
| WO2019219714A1 (en) | 2018-05-15 | 2019-11-21 | Novo Nordisk A/S | Compounds capable of binding to melanocortin 4 receptor |
| JP2021526130A (ja) | 2018-06-12 | 2021-09-30 | ブイティーブイ・セラピューティクス・エルエルシー | インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用 |
| WO2020053414A1 (en) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Bicyclic compounds capable of acting as melanocortin 4 receptor agonists |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| CN117209448A (zh) * | 2023-09-13 | 2023-12-12 | 济宁医学院 | 含(苯并)噻唑硫代/硒代乙酰胺及其衍生物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3776917A (en) * | 1972-06-05 | 1973-12-04 | Schering Corp | 2-amino-6-phenalkyl-aminopyridines and derivatives thereof |
| JPS5564592A (en) * | 1978-11-10 | 1980-05-15 | Teijin Ltd | Thiazolo 3, 2-a pyrimidine derivative, its preparation, and drug comprising it |
| JPS62153273A (ja) * | 1985-12-26 | 1987-07-08 | Tokuyama Soda Co Ltd | ピラゾ−ル化合物 |
| BR0009486B1 (pt) * | 1999-03-29 | 2011-03-09 | composto que compreende uma amida, composição farmacêutica que compreende esse composto, seu uso e processo para a preparação do mesmo. |
-
2001
- 2001-07-11 CN CNB01813050XA patent/CN1184214C/zh not_active Expired - Fee Related
- 2001-07-11 JP JP2002514115A patent/JP4138478B2/ja not_active Expired - Fee Related
- 2001-07-11 DK DK01967150T patent/DK1305301T3/da active
- 2001-07-11 AU AU8760001A patent/AU8760001A/xx active Pending
- 2001-07-11 PT PT01967150T patent/PT1305301E/pt unknown
- 2001-07-11 MX MXPA03000365A patent/MXPA03000365A/es active IP Right Grant
- 2001-07-11 ES ES01967150T patent/ES2243547T3/es not_active Expired - Lifetime
- 2001-07-11 CA CA002416229A patent/CA2416229C/en not_active Expired - Fee Related
- 2001-07-11 DE DE60111534T patent/DE60111534T2/de not_active Expired - Lifetime
- 2001-07-11 AU AU2001287600A patent/AU2001287600B2/en not_active Ceased
- 2001-07-11 WO PCT/EP2001/007994 patent/WO2002008209A1/en not_active Ceased
- 2001-07-11 BR BR0112658-0A patent/BR0112658A/pt not_active IP Right Cessation
- 2001-07-11 EP EP01967150A patent/EP1305301B1/en not_active Expired - Lifetime
- 2001-07-11 KR KR1020037000822A patent/KR100556323B1/ko not_active Expired - Fee Related
- 2001-07-11 AT AT01967150T patent/ATE297907T1/de not_active IP Right Cessation
- 2001-07-13 US US09/905,152 patent/US6486184B2/en not_active Expired - Fee Related
- 2001-07-18 AR ARP010103437A patent/AR032626A1/es active IP Right Grant
- 2001-07-18 PA PA20018522701A patent/PA8522701A1/es unknown
- 2001-07-19 UY UY26850A patent/UY26850A1/es not_active Application Discontinuation
- 2001-07-19 PE PE2001000731A patent/PE20020335A1/es not_active Application Discontinuation
- 2001-07-20 GT GT200100146A patent/GT200100146A/es unknown
-
2002
- 2002-06-25 US US10/179,717 patent/US6608218B2/en not_active Expired - Fee Related
-
2003
- 2003-01-07 ZA ZA200300173A patent/ZA200300173B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US6608218B2 (en) | 2003-08-19 |
| US6486184B2 (en) | 2002-11-26 |
| DE60111534D1 (de) | 2005-07-21 |
| UY26850A1 (es) | 2002-01-31 |
| DK1305301T3 (da) | 2005-10-17 |
| JP2004504388A (ja) | 2004-02-12 |
| JP4138478B2 (ja) | 2008-08-27 |
| MXPA03000365A (es) | 2003-05-27 |
| ATE297907T1 (de) | 2005-07-15 |
| ES2243547T3 (es) | 2005-12-01 |
| AR032626A1 (es) | 2003-11-19 |
| CN1184214C (zh) | 2005-01-12 |
| BR0112658A (pt) | 2003-06-24 |
| PT1305301E (pt) | 2005-09-30 |
| ZA200300173B (en) | 2004-04-07 |
| EP1305301A1 (en) | 2003-05-02 |
| KR20030016419A (ko) | 2003-02-26 |
| CA2416229A1 (en) | 2002-01-31 |
| CN1443177A (zh) | 2003-09-17 |
| US20020042512A1 (en) | 2002-04-11 |
| PA8522701A1 (es) | 2002-10-24 |
| KR100556323B1 (ko) | 2006-03-03 |
| CA2416229C (en) | 2007-09-18 |
| GT200100146A (es) | 2002-07-04 |
| AU8760001A (en) | 2002-02-05 |
| AU2001287600B2 (en) | 2006-07-13 |
| DE60111534T2 (de) | 2006-05-11 |
| US20020198200A1 (en) | 2002-12-26 |
| EP1305301B1 (en) | 2005-06-15 |
| WO2002008209A1 (en) | 2002-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020335A1 (es) | Acetamida de benceno de alfa-acil- y alfa-heteroatomo-sustituido como activadores de la glucoquinasa | |
| PE20011310A1 (es) | Alquinil fenil amidas heteroaromaticas como activadores de la glucokinasa | |
| PE20020753A1 (es) | Heteroaromaticos fusionados como activadores de la glucoquinasa | |
| PE20020056A1 (es) | Fenil amidas para-aril o heteroaril sustituidas como activadores de la glucoquinasa | |
| PE20001584A1 (es) | Activadores de la glucoquinasa | |
| PE20011022A1 (es) | Compuestos trans olefinicos activadores glucoquinasa | |
| PE20011313A1 (es) | Activadores de glucoquinasa que contienen hidantoina | |
| PE20020771A1 (es) | Pirrolidina fusionada con ciclopropilo como inhibidores de dipeptidil peptidas iv | |
| ES2184482T3 (es) | Benzazoles, derivados del venzoxazol, el benzotiazol y el bencimidazol. | |
| PE20020049A1 (es) | Fenilamidas para amina sustituidas como activadores de glucoquinasa | |
| PE20040071A1 (es) | Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion | |
| CA2419416A1 (en) | Tetrazolyl-phenyl acetamide glucokinase activators | |
| UY27357A1 (es) | Nuevos agentes antidiabéticos . | |
| ATE163012T1 (de) | N-substituierte 4-pyrimidinamine und - pyrimidindiamine, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel | |
| PE20011066A1 (es) | PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS | |
| ES2174757B1 (es) | Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares. | |
| CO4770950A1 (es) | Composicion antiparasitaria para tratamiento y proteccion de animales de compania | |
| PE20021066A1 (es) | Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, asi como preparados farmaceuticos que las contienen | |
| MX9702670A (es) | Derivado de azol. | |
| PE20031037A1 (es) | Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades | |
| PE20040375A1 (es) | Amino-piperidinas 4,4-disustituidas como ligandos de receptores de melanocortina | |
| DE3866415D1 (de) | Mittel zur insekten- und milbenabwehr. | |
| AR003503A1 (es) | Composiciones para controlar hongos perjudiciales que contiene fenazaquin y amidas heterociclicas como agentes activos y metodo para controlar los hongosmencionados, con aplicacion de dicha composicion. | |
| PE20070829A1 (es) | Inhibidores cetp heterociclicos | |
| AR002741A1 (es) | Benciloxicarbonilguanidinas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico asi como medicamentoque las contiene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |